Panitumumab

Description

Panitumumab is a recombinant, fully human IgG2 kappa monoclonal antibody that is highly selective for the epidermal growth factor receptor (EGFR), and it is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC) with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Overexpression of EGFR is detected in many human cancers, including those of the colon and rectum. Panitumumab blocks the binding of ligands such as epidermal growth factor (EGF) and transforming growth factor (TGF-a) to various EGFR-expressing cell lines, which results in inhibition of EGF-dependent tumor cell activation, induction of apoptosis, and decreased pro-inflammatory cytokine and vascular growth factor production. In vitro, panitumumab binds EGFR with high affinity (KD ? 50pM; IC50 ? 3 nM) in human cervical epidermal cell line A-431. .

Originator

Abgenix (US)

Uses

Antineoplastic.

brand name

Vectibix

Clinical Use

Monoclonal antibody:
Treatment of metastatic colorectal cancer

Drug interactions

Potentially hazardous interactions with other drugs
Cytotoxics: avoid with bevacizumab, fluorouracil, irinotecan and oxaliplatin.
Folinic acid: avoid concomitant use.
Live vaccines: avoid concomitant use.

Metabolism

Saturable elimination mediated via reticuloendothelial system, and internalisation and degradation of EGFR.